Introduction
Outcomes measurement and public reporting are here to stay whether we like it or not. Even if your personal results are great, there is always room for improvement and performance across the healthcare spectrum is highly variable and often suboptimal. Costs are an unsustainable proportion of the GNP, and excess costs are often related to suboptimal care and preventable complications. Quality, safety, and value data are the keywords in modern healthcare. We are all becoming more aware of CMS quadruple aims, CMS Hospital Compare, CMS Value-based Purchasing, HAC Reduction Initiative, Hospital Readmission Reduction Program, Overall Hospital Star Rating, MACRA, MIPS, Advanced APMs, and so on. Joint Commission certification of specialty centers requires data and outcomes. And there is the commercial media obsession: USNWR, ProPublica, HealthGrades, RateMD-this will continue and expand regardless of what we do.
Why Do We Measure Outcomes?
The fundamental rationale for collecting data and analyzing healthcare outcomes in the broadest sense is to assess the quality or effectiveness of care. This of course creates a platform and a basis that may ultimately serve to guide improvement in quality of care, improvement in patient care experience, and possibly even reduce the per capita cost of healthcare. In general, healthcare organizations measure outcomes for several reasons . . . identify variations of care, provide evidence about interventions that work best for certain types of diseases, compare the effectiveness of various treatments and procedures, and reveal areas in which interventions or changes in processes of care could bring about improvements in care. In our specialty, we measure and feedback results to centers treating congenital heart disease because: a. It is the basis for data-driven improvement initiatives, b. Other entities (eg, your hospital quality department, state regulators, commercial media) have access to other data sources (eg, claims) and may make unwarranted assertions about your performance. By having clinically based data collected by clinicians and their surrogates using a standardized data collection tool or platform, you can identify and remediate any unfavorable trends before they become apparent to others. Also, you have the "gold standard" to refute anyone else who comes up with unfounded criticisms, and c. It is our professional responsibility to know, based on objective data, our personal and other faculty outcomes, and our own center's performance.
Fortunately, we utilize the Society of Thoracic Surgeons (STS) National Database, which is the benchmark database in the healthcare industry. For three decades, centers performing cardiothoracic surgery have relied upon the STS Databases for clinical data analysis and feedback to provide a platform for center-level quality assessment while also benchmarking national-level aggregated outcomes. More recently, voluntary public reporting of center-level outcomes has become an optional feature of STS Database participation. Public reporting of congenital heart surgery outcomes data has received increasing attention recently. The impetus for reporting efforts reflects the interests of and input from numerous stakeholders including patients, families, and affiliated organizations who have advocated for more transparent sharing of hospital outcomes data to better inform decisions. All of this has evolved in parallel with government agencies, the media and professional societies having initiated platforms for sharing outcomes data with the public. Much of these efforts have centered on two critical aspects of public reporting: (1) improving case mix adjustment and (2) optimizing methods for sharing outcomes data with the public. Case mix can vary widely across centers, including both the type and the frequency of different congenital heart defects treated, patient comorbidities, and risk factors such as genetic syndromes and noncardiac anomalies. It is important to take differences in case mix into account when assessing a program's outcomes in order to make an accurate assessment of performance in the context of a center's own unique case mix. This is important for many reasons not least of which is to avoid penalizing those caring for higher risk patient populations. Failure to account for differences in patient comorbidities and risk factors can result in an inaccurate characterization of a hospital's performance. Herein lies the current controversy: (1) Does the current STS Congenital Heart Surgery Database (CHSD) and its methodology and analytics accurately measure outcomes, account for case mix, and ultimately reflect a given program's performance; and (2) Should the current presentation of the outcome data on the STS website be revamped?
What Is the Purpose of Public Reporting?
The purpose of public reporting in congenital heart surgery is (1) to help to improve the overall care of patients, (2) to show whether the outcomes of a hospital/program are consistent with an inference that they are safe and competent, and (3) to provide the public with measures of center level outcome that are based upon data that have been collected and analyzed in a uniform fashion across the vast majority of North American centers, and provide this within the context of risk models that are derived and periodically updated using the aggregate data set from all participating centers, while the center-level analysis is tailored to reflect the unique case mix of that center.
It is our ethical responsibility to public report-it provides patients and families with additional information upon which to make an informed decision-and currently 84.6% of all programs appear to believe in this ethos, the highest frequency of our specialty to publicly report. The realization that you are going to report your results may be an impetus to fix festering problems, for example, a chronically underperforming staff member, or to stimulate your hospital to invest additional resources in your program, for example, need for new equipment, staff, dedicated intensive care unit, dedicated anesthesia, nurse practitioners, physician assistants, nurses, and so on. Finally, others are going to grade you using metrics that may be inaccurate and misleading. We need a publicly reported gold standard based on verifiable data and valid analytics to counter this. The current methodology and analytic system applied to the STS Database results in a finding that 83% of programs are achieving outcomes that are as expected for their own unique case mix (measured on the basis of programmatic risk-adjusted operative mortality), 9% have lower than expected mortality, and 8% higher than their expected level. In other words, 92% of all programs are performing very good congenital cardiac surgery.
Some members of our specialty are frustrated, disgruntled, and upset with this format for two main reasons: (1) they have concerns that the current database and analytics based on a "procedure-based" approach may have flaws and may not fully account for complex procedures and (2) the display of the data on the STS public reporting website may be suboptimally represented or explained and seems to lend itself to direct center-tocenter comparisons, which is not the intent of the STS, nor is it consistent with the type of statistical analysis. Finally, some are concerned that the information displayed inaccurately reflects a program's performance. This discontent has resulted in petitions, letters, e-mails, and phone calls to me and other members of STS leadership with a plea to abandon, a "moratorium," and revamp the current STS CHSD platform. However, it is important to note that, in response to this communication, many of you have sent STS leadership the opposite message, stating that you fully support the efforts of the STS CHSD and public reporting, have confidence in the mortality risk model, and do not agree with the stance being taken by others in our specialty.
As a member of STS leadership, I want to emphasize and assure you that all of these issues are being taken seriously and are being carefully examined, and action is being taken to improve the current platform. With this in mind, the current strengths and weaknesses of the present STS system are summarized as follows:
Strengths of the STS Congenital Quality Program 1. All STS congenital measures use standardized international nomenclature, which is being incorporated into International Classification of Diseases, Eleventh Revision. This means that fortunately, this nomenclature will not just continue to be the "language" of clinical registries, but for the first time it will also be used in administrative and claims databases. 2. Penetration of the STS CHSD is estimated to be >95% of US congenital programs, which provides a truly representative national benchmark. 1 Recognizing that complications and resource utilization are important quality markers, a morbidity score/category system was also created, 6 similar to STS STAT mortality categories. Most recently, in 2019, work was completed on an important risk-adjustment refinementthe addition of more granular adjustment for specific anatomic, chromosomal, and syndrome risk factors to the mortality model. 7 In the next evolutionary step, we have developed a comprehensive composite measure 8, 9 including mortality, morbidity, and length of stay. This provides a much broader perspective on quality, and it mirrors numerous similar measures in adult cardiac surgery. 8. Importantly, all risk model and performance measure development have been published in the peer-reviewed literature.
Limitations of the STS Congenital Quality Program
1. Because of large variations in case mix among programs, and the inherently large number of diagnoses and procedures in congenital heart surgery, it is challenging to capture, analyze, and aggregate outcomes for all procedures and their combinations at all programs.
2. For new and innovative procedures, most of the STS CHSD experience may be represented by the results of the one or two programs that developed the procedure, and whose results are typically very good. This might discourage other programs from adopting these more challenging yet superior approaches. The original innovators' results may also appear to be "as expected" rather than "lower than expected (mortality)" regardless of how good they might be, as they are their own benchmark. Some would argue that the ability to do these complex new procedures with reasonable mortality is itself a marker of high quality and perhaps these should be excluded from the composite assessment.
The Society of Thoracic Surgeons does not currently
have individual procedure-specific risk models, mainly because of the small numbers at the individual procedure level. For several years, however, the database has incorporated collection of "procedure-specific factors." Development of individual "benchmark procedures" specific risk models is currently being examined. 4. We do not yet report congenital composite measures in feedback reports to participants, nor are they included in our public reporting. 5. Many participants do not understand that there is nothing magical about "star ratings." They are simply a user-friendly representation of three categories: higher or lower than expected mortality, and as expected. 6. Many participants and patients do not understand that a hospital's star rating only applies to its performance in the context of its own specific case mix. One cannot and should not infer from a star rating what a hospital's outcomes and performance might be in the context of a case mix that is either more or less challenging than their own. And importantly, star ratings and riskadjusted mortality rates should not be used to compare one specific program to another and should not be used to rank programs. 7. Commercial media might take our publicly reported data from the STS website and misuse it-for example, using our results to help them rank hospitals, a practice with which we strongly disagree. We have no control over this.
What Are We Doing Now?
A variety of quality measurement options are being explored with the objective of determining a set of metrics that are widely accepted by the congenital community. Parallel efforts currently being examined include progressive refinement of the current metrics, exploration of a benchmark set of procedures, and the entirely new approach of a diagnosis-based analytic being studied by Dr John Mayer and biostatistician Dr Sharon-Lise Normand at the Harvard T.H. Chan School of Public Health. Some literature and panel discussion/forums at National Transparency symposiums appear to show that parents of children with congenital heart disease identify survival statistics, surgeon-specific experience, and complication rates as the most important outcome measures to report publicly. In addition, some parents prefer mortality data to be presented in a benchmark procedure-specific format. These preferences are also being factored into potential changes made in public reporting moving forward. Public reporting must continue-abandoning this program would be the wrong thing to do ethically and professionally, and it would send a terrible message to the outside world-this would be a catastrophic mistake. Some suggested changes include reporting on ten benchmark procedures . . . this may or may not be adequate. Any such measure should ideally include risk adjustment and should be paired with a more comprehensive measure (such as our overall Adjusted Mortality Rate [AMR] measure) that captures all major cases in a given program. There needs to be an overall programmatic report card, not just ten benchmark procedure that reflects only a third or less of a program's practice. Additional suggestions could include overall risk-adjusted morbidity and mortality, composite measures, outcomes for benchmark procedures, routine CUSUM OR VLAD plots, procedure-specific and overall volumes, readmissions and reinterventions, risk-adjusted neurodevelopmental outcomes, patient-reported outcomes, and patient (family) experience of care. Program auditing should be as rigorous as possible, to insure mortality/morbidity data are accurate and there is no over or under coding. Greatly expanded educational efforts should address the correct uses of indirectly standardized outcomes/star ratings or O:E ratios. There should be disclaimers regarding inappropriate uses of STS scores or ratings by commercial media. There should be mechanisms to credit the innovators of new and better procedures. There should be methods to facilitate the training of other programs that wish to adopt these new techniques and ways to monitor their learning phase to assure public safety. Finally, programs that have a "higher than expected" mortality should have a site visit and mechanism for a remediation plan to help facilitate improvement.
Keep in Mind
1. No risk model or performance measure ever has been, is now, or ever will be perfect, 2. Work is currently underway to further refine existing models and measures. At the same time, new approaches are being explored by a group led by Dr John Mayer and colleagues, who are pursuing new and different ways of measuring and reporting performance, but it will be some time before we know if they are truly "better" than we have now, 3. Whatever new risk models, performance measures, and approaches are developed, there will be those in our specialty who will vehemently disagree with them, 4. Now, and when new models and measures have been proposed and evaluated, we must commit to accepting and using the best available methodologies developed by our clinical and statistical colleagues, while recognizing that there will always be room for further improvement-it is an ongoing iterative process, 5. In the measurement of adult cardiac surgery performance, which many in the congenital community regard as an almost trivial exercise compared to the complexities of our specialty, there were no publicly reported outcomes of any kind until the mid-1980s, and no risk-adjusted outcomes were available from clinical registries until 1990. In 2007, when the first STS composite measure was developed, most assessments of adult cardiac surgical quality were limited to one outcome-mortality-and one operation-coronary artery bypass grafting, occasionally adding a single valve procedure such as aortic valve replacement. It has taken more than a decade to develop an expanding family of STS composite measures (mortality and morbidity) for most adult cardiac procedures, and now the general thoracic and congenital operations.
Because the early adult cardiac measures were imperfect and suboptimal, should we have done nothing these past two decades, waiting for "perfection"?? Since our earliest operations in congenital heart surgery were not perfect and often produced suboptimal results, should we have abandoned them and done nothing until we had "perfect" operations? The answer is obvious-we do the very best we can in the current moment with what is available, we learn through experience the pros and cons of our current approaches and use that knowledge to progressively improve for the future. That's what we have done in the clinical practice (science) of congenital heart surgery, and it is no different in the science of measurement. If we wait for the perfect solution in either of these situations, we will never progress, and we will certainly never achieve that perfection.
In the midst of this pandemonium in our specialty, I have come to realize, understand, and accept that no system will ever be perfect and that self-serving viewpoints need to be avoided. This is an iterative process that will always undergo periodic methodology reexaminations and upgrades; that is what we are doing now. We hear your concerns. Circulating more petitions and letters of discontent are counterproductive at this juncture and only serve to fracture more personal and professional relationships and also results in the public having less confidence in our specialty. A moratorium on the STS CHSD is not an option. The current model is not perfect, but it is good and it is validated, and whether we like it or not . . . it is the data. I disagree with the recent request to publicly report unadjusted, raw mortality outcomes. That strategy would only create more misconceptions and would reflect naivete and ignorance on the part of our specialty and profession. It would be a monumental step backward to the mid-1980s when there was no risk adjustment available in cardiothoracic surgery or anywhere else in healthcare, a deficiency which was the primary motivation for development of the STS Database in the first place. It concerns me that among my respected colleagues there are some who are arguing for a return to this deeply flawed approach. Whether their current level of frustration is primarily with national rankings, with star ratings, or with their perception of shortcomings of the STS' current Congenital Heart Surgery Mortality Risk Model, it is counter-productive, and short-sighted to propose that we abandon the current model, turn the clocks back, and pretend that providing the public with raw, non-risk-adjusted outcome data is a way to "inform" them. For many such complainants, it is their own institutions that care for some of the most challenging and highest risk patients, whose results would be least reliably reported because of failure to account for case mix and failure to adjust for risk using the most comprehensive inclusive model available.
Analytics, presentation, and reporting of the data can and will be improved. We have a responsibility and we owe it to our patients, the public and ourselves to make the current system better. The timelines for many of these changes are 2020. Remember, public reporting is voluntary . . . you can choose what you think is best for you and your program during this improvement phase. My plea is that we persevere and work together to achieve this goal. This is an important time for unity, not division, as we face threats from other claimsbased systems that will report our data for us if we do not come together. We should apply the best features of the current analytics, add new methodologies to improve upon what we currently have, and then publicly report the most meaningful elements of the data in a clear and understandable manner.
